J. Nat. Prod. 1998, 61, 1509-1512 1509 Cytotoxic Geranyl Stilbenes from Macaranga schweinfurthii John A. Beutler,† Robert H. Shoemaker, Tanya Johnson, and Michael R. Boyd* Laboratory of Drug Discovery Research and Development, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, Maryland 21702-1201 Received May 18, 1998 Downloaded by NATL CANCER INST FCRDC on September 8, 2009 | http://pubs.acs.org Publication Date (Web): October 24, 1998 | doi: 10.1021/np980208m Three novel geranyl stilbenes, schweinfurthins A, B, and C (1, 2, and 3), were isolated from the Cameroonian plant Macaranga schweinfurthii (Euphorbiaceae) and their structures determined by NMR and mass spectral methods. The cytotoxicity profile of the schweinfurthins tested in the NCI 60-cell screen was similar to that of the stelletins and cephalostatins, suggesting that these structurally diverse natural products may share similar mechanisms of cytotoxicity. The genus Macaranga is one of the largest genera of the Euphorbiaceae, with approximately 300 species.1 Previously reported compounds from the genus include a prenyl stilbene, vedelianin2 and a geranyl flavonol3 from M. vedeliana, antibacterial prenylated flavanones from M. pleiostemona,4 chromenoflavones from M. indica,5 and a diterpene from M. tanarius.6 A number of species of Macaranga are substantial sources of hydrolyzable tannins.7 No phytochemistry has been previously reported on M. schweinfurthii, and none of the above-cited compounds is documented to be cytotoxic. Our preliminary testing of Macaranga extracts available from the NCI repository found 11 samples from eight species of Macaranga, including M. schweinfurthii, to be devoid of phorbol ester bioactivity.8,9 For the present study we selected an organic extract of M. schweinfurthii Pax based upon its prominent cytotoxicity toward several human tumor cell lines in the NCI panel,10,11 notably the CNS tumor-derived lines SF-295 and SF-539. Here we describe the bioassay-guided isolation and structure elucidation of the compounds responsible for this cytotoxicity. Results and Discussion Batch elution from diol bonded-phase media, Sephadex LH-20 permeation, C-18 vacuum liquid chromatography, and C-18 HPLC led to compounds 1 and 2 as the major cytotoxic constituents. Compound 3 was found as an inactive major congener. Compound 1 was an optically active yellow glass [R]D +51.8° with a molecular formula of C34H44O6, as determined by HRFABMS. The UV maximum at 331 nm was consistent with a stilbene such as vedelianin,2 and the 1H and 13C NMR spectra of 1 (Table 1) shared many features with this compound. The molecular formula of compound 1 differed by C5H8 from vedelianin (4), consistent with the presence of an additional prenyl group. HMQC and HMBC spectra confirmed that the planar structure of 1 was otherwise identical to vedelianin, and HMBC correlations between a signal at δ 2.05 (H-6′′) and a methylene 13C resonance at δ 40.9 (C-5′′), as well as δ 134.8 ppm (C-3′′), established the point of substitution for the additional prenyl group. The congruency of chemical shifts and scalar couplings in the cyclohexyl ring and similar sign and magnitude of optical rotations indicated that 1 possessed the same relative stereochemistry as 4. † SAIC-Frederick, NCI-FCRDC, Frederick, MD 21702-1201. Compound 2 had the formula C35H46O6 by HRFABMS, differing from 1 by an additional CH2. This was also evident in the 1H NMR (Table 2) by presence of a 3H singlet at δ 3.83 and a 13C NMR resonance at δ 56.4. An HMBC correlation from this methyl group to the resonance at δ 150.1 placed the methoxyl group at C-5, which was shifted 3 ppm compared to compound 1. Further HMBC correlations for 2 (data not shown) supported the assigned structure. Schweinfurthin C (3) had the molecular formula C34H44O4 by HRFABMS. The absence of 13C NMR resonances between 70 and 80 ppm (Table 3) indicated that this compound lacked the vicinal diol functionality of compounds 1 and 2. There were six methyl singlets in the 1H NMR spectrum (from δ 1.55 to δ 1.75) and four vinyl triplets. 10.1021/np980208m This article not subject to U.S. Copyright. Published 1998 by the Am. Chem. Soc. and the Am. Soc. of Pharmacogn. Published on Web 10/24/1998 1510 Journal of Natural Products, 1998, Vol. 61, No. 12 Table 1. 125 MHz) Downloaded by NATL CANCER INST FCRDC on September 8, 2009 | http://pubs.acs.org Publication Date (Web): October 24, 1998 | doi: 10.1021/np980208m carbon no. 1 2 3 4 4a 5 6 7 8 8a 9 9a 10a 11 12 13 1′ 2′ 3′ 4′, 8′ 5′, 7′ 6′ 1′′ 2′′ 3′′ 4′′ 5′′ 6′′ 7′′ 8′′ 9′′ 10′′ MeO-5 13C NMR Data for 1, 2, and 4 (δ in ppm, CD3OD, 13C 13C shift 2, DEPT multiplicity shift 1 39.1 78.8 71.7 44.6 78.2 147.0 111.1 130.8 120.5 124.2 23.9 48.8 137.6 16.3 29.4 22.0 128.7 127.4 141.9 105.7 × 2 157.2 115.9 23.2 124.6 134.9 13.5 40.9 27.8 125.6 131.9 17.7 25.8 39.1, s 78.7, d 71.7, d 44.7, t 78.0, s 150.1, s 108.3, d 130.6, s 121.7, d 124.3, s 23.9, t 48.6, d 137.5, s 16.2, q 29.3, q 21.9, q 128.5, d 127.6, d 143.3, s 105.8 × 2, d 157.2 × 2, s 115.9, s 23.2, t 124.5, d 134.8, s 16.5, q 40.9, t 27.7, t 125.5, d 131.9, s 17.7, q 25.8, q 56.4, q 13C shift 44 39.0 78.7 71.7 44.5 78.0 146.8 111.0 130.7 120.5 124.1 23.8 48.6 137.6 16.2 29.3 22.0 128.8 127.3 141.8 105.9 157.1 115.9 23.3 124.5 131.3 25.9 17.9 HMQC to 1H for 2 3.30 4.14 2.34, 1.94 6.91 6.84 2.75 1.74 1.76 1.10 1.40 6.87 6.77 6.47 3.30 5.25 1.05 1.94 2.05 5.07 1.56 1.62 3.83 Table 2. 1H NMR of Schweinfurthin B (2) (CD3OD, 500 MHz) proton no. COSY to 1H difference NOE to 1H 2 3 4 4a 5-MeO6 8 9 9a 11 12 13 1′ 2′ 4′, 8′ 1′′ 2′′ 4′′ 5′′ 6′′ 7′′ 9′′ 10′′ 4.14 3.30, 2.34, 1.94 1.94 2.34 3.30, 2.34, 1.94 4.14, 1.94, 1.40 6.83 6.91 1.74 2.75 6.77 6.87 5.25 3.30 2.05 1.94 2.05, 1.56, 1.62 3.30, 1.94, 2.05 Beutler et al. Table 3. Results of In Vitro Time-Course Experiments with Schweinfurthins A (1) and B (2) in Sensitive (SF-295) and Resistant (A549) Cell Linesa compound protocol 1h 1 h washout 48 h a 1 A549 43 20 3.7 SF-295 47 0.06 <0.00001 2 A549 >100 80 7.1 SF-295 >100 2.9 0.009 Values are IC50 in µg/mL. phenolic carbon resonances at δ 144.2 (C-1) and δ 146.1 (C-2), establishing this ring as a 3,5-disubstituted 1,2catechol. The purified compounds were evaluated in an in vitro time-course experiment using SF-295 and a resistant cell line, A-549. A 1-h treatment with compounds 1 and 2 led to negligible cytotoxicity, indicating that the compounds were not cytotoxic through a rapid mechanism such as membrane lysis. A 1-h treatment followed by compound washout and evaluation at 48-h demonstrated a modest differential cytotoxicity for each compound, while continuous 48 h treatment with the compounds generated a robust differential (Table 3). Compounds 1 and 2 were tested in the 60-cell line human tumor cancer screen.10 Schweinfurthin A (1) showed a mean panel GI50 of 0.36 µM, while schweinfurthin B (2) was slightly less potent, giving a mean panel GI50 of 0.81 µM. The brain tumor (CNS) subpanel was the most sensitive to both compounds, while the ovarian cancer cell lines were uniformly resistant. The most sensitive cell line was the CNS line SF-295, for which schweinfurthin A (1) gave a GI50 of 11 nM and a TGI of 52 nM. Other sensitive lines included leukemia (CEM, HL-60, MOLT-4, and RMPI8226) and lung (HOP-62), CNS (SF-539 and SNB-75), renal (786-0, RXF-393, and UO-31), and breast (HS 578T) cancers. The differential cytotoxicity profiles are further documented in the Experimental Section. The NCI 60-cell mean-graph cytotoxicity profiles showed little or no resemblance to those of any of the profiles in the NCI’s standard agents database.12 However, when analyzed at the GI50 and TGI levels of response using the Compare program,12,13 the schweinfurthins showed relatively high correlations to stellettin A14 (e.g., 0.75, 0.75) and cephalostatin 115 (e.g., 0.59, 0.66). The cell lines sensitive to these compounds differ substantially in many known characteristics including in vitro doubling time, DNA repair phenotype, and MDR status. No common biochemical feature of these lines is apparent which could explain their particular sensitivity to these compounds. These results suggest that the schweinfurthins may share with the stellettins and cephalostatins similar mechanism(s) of cytotoxicity. Experimental Section 1.62 These observations were accountable to a stilbene with two geranyl chains and four phenolic groups. Although the NMR data indicated that one side chain was attached in the same fashion as in 1 and 2, the other geranyl group was different. The second geranyl substituent was placed by the HMBC correlations of the aromatic proton at δ 6.67 (H-5) to the methylene carbon resonance at δ 29.1 (C-7) and the phenolic carbon at δ 144.2 (C-1). The aromatic ortho-coupled proton (δ 6.81, H-3) was correlated to the General Experimental Procedures. NMR spectra were acquired on a Varian VXR-500 spectrometer with an inverse detection probe. Optical rotations were obtained on a PerkinElmer model 204 polarimeter. UV spectra were acquired using a Beckman DU640 spectrophotometer, while IR spectra were obtained on a Perkin-Elmer Spectrum 2000 FT-IR spectrophotometer. FABMS were obtained on a JEOL SX102 mass spectrometer operated at an accelerating voltage of 10 kV. Samples were desorbed from a nitrobenzyl alcohol matrix using 6 keV xenon atoms. Mass measurements in FAB were performed at 10 000 resolution using electric field scans and the matrix ions as the reference material. Plant Material. Leaves of Macaranga schweinfurthii Pax were collected by D. W. Thomas (Thomas 6771, voucher in Downloaded by NATL CANCER INST FCRDC on September 8, 2009 | http://pubs.acs.org Publication Date (Web): October 24, 1998 | doi: 10.1021/np980208m Geranyl Stilbenes from Macaranga Missouri Botanical Garden, collection Q66P364) in the vicinity of Mundemba, Ndian Division, Korup National Park, Cameroon, in March 1987. Cytotoxicity Bioassay. Two cell lines from the NCI CNS screening panel (SF-295 and SF-539) were chosen for a twoday cytotoxicity assay16 to monitor fractionation. Isolation. Ground, dry leaves (425 g) were extracted with CH2Cl2-MeOH (1:1 v/v) and then MeOH; the solvent was evaporated to yield 22.4 g of organic extract. Of this extract 5.0 g was coated on 25 g of diol media (YMC) and eluted with 500 mL each of hexane, CH2Cl2, EtOAc, Me2CO, and MeOH in sequence. The EtOAc fraction (1.55 g) contained ca. 94% of the cytotoxicity and was further fractionated by permeation though Sephadex LH-20 using CH2Cl2-MeOH (1:1 v/v). The fourth of five fractions collected (0.51 g) contained ca. 99% of the cytotoxicity. It was dissolved in MeOH, coated on 10 g of flash grade C18 media (YMC), and eluted with 200 mL each of 50% MeOH, 70% MeOH, 80% MeOH, 90% MeOH, and MeOH. The 70% MeOH fraction was the most cytotoxic. HPLC of this fraction in 25-mg aliquots on C18 (21 × 250 mm, 60 Å, Rainin Dynamax column) using a linear 70-100% MeOH gradient yielded 50 mg of schweinfurthin A (1), 38 mg of schweinfurthin B (2), and 25 mg of schweinfurthin C (3). Compound Data. Schweinfurthin A (1): NSC#696119; yellowish solid; [R]D +51.8° (c 2.0, EtOH); UV (EtOH) λmax 224 nm (log ǫ 4.48), 331 nm (4.58); IR (film) 3419 (br), 1710, 1592, 1496, 1428, 1374, 1258, 1046, 959, 930 cm-1; 1H NMR 6.82 (d, 1H, J ) 16 Hz, H-1′), 6.80 (d, 1H, 2, H-6), 6.71 (d, 1H, 16, H-2′), 6.69 (d, 1H, 2, H-8), 6.46 (s, 2H, H-4′, 8′), 5.25 (tq, 1H, 7.1, 1.2, H-2′′), 5.07 (t pentet, 1H, 7.1, 1.4, H-7′′), 4.13 (d, 1H, 2.4, H-3), 3.35 (m, 4H, H-2, 9a, 1′′), 2.71 (m, 2H, H-9), 2.35 (d, 1H, 13, H-4a), 2.04 (t, 2H, 7.3, H-6′′), 1.95 (t, 2H, 7.3, H-5′′), 1.94 (m, 1H, H-4), 1.76 (s, 3H, H-11), 1.62 (s, 3H, H-10′′), 1.56 (s, 3H, H-9′′), 1.40 (s, 3H, H-13), 1.08 (s, 3H, H-12), 1.07 (s, 3H, H-4′′); 13C NMR, see Table 1; HRFABMS (noba, positive mode) M+ 548.3113 (calcd for C34H44O6 548.3138). Schweinfurthin B (2): NSC#696118, yellowish solid; [R]D +44.7° (c 1.0, EtOH), UV (EtOH) λmax 223 nm (log ǫ 4.44), 331 nm (4.52), IR (film) 3433 (br) 1708, 1588, 1493, 1431, 1374, 1257, 1156, 1086, 1043, 956, 909, 849 cm-1; 1H NMR (CD3OD, 500 MHz) δ 6.91 (1H d, J ) 2.0 Hz, H-6), 6.87 (1H d, J ) 16 Hz, H-1′), 6.83 (1H d, J ) 2.0 Hz, H-8), 6.77 (1H d, J ) 16 Hz, H-2′), 6.47 (2H br s, H-4′ and H-8′), 5.25 (1H tq, J ) 7.2, 1.2 Hz, H-2′′), 5.07 (1H t pentet, J ) 7.2, 1.4 Hz, H-7′′), 4.14 (1H q, J ) 3.4 Hz, H-3), 3.83 (3H s, 5-MeO-), 3.30 (obscured by solvent, H-2 and H-1′′), 2.75 (2H m, H-9), 2.34 (1H dd, J ) 13.9, 3.3 Hz, H-4), 2.05 (2H m, H-6′′), 1.94 (3H m, H-4a and H-5′′), 1.76 (3H s, H-11), 1.74 (1H m, H-9a), 1.62 (3H s, H-10′′), 1.56 (3H s, H9′′), 1.40 (3H s, H-13), 1.10 (3H s, H-12), 1.08 (3H s, H-4′′); 13C NMR, see Table 1; FABMS (noba, positive mode) 562, 532, 460, 407, 307, 289; HRFABMS (noba, positive mode) M+ 562.3308 (calcd for C35H46O6 562.3294). Schweinfurthin C (3): NSC#698298; UV λmax 330 nm (log ǫ 4.03), EtOH, IR 3423 (br), 1590, 1499, 1440, 1302, 1036, 958, 849 cm-1; 1H NMR (CD3OD, 500 MHz) δ 6.81 (1H m, J ) 2.3 Hz, H-3), 6.77 (1H d, J ) 16 Hz, H-1′), 6.67 (1H m, J ) 6.3, 2.2 Hz, H-5), 6.63 (1H d, J ) 16 Hz, H-2′), 6.43 (2H s, H-4′ and H-8′), 5.33 (1H t, J ) 7.4, H-8), 5.24 (1H t, J ) 7.4 Hz, H-2′′), 5.11 (1H t, J ) 7.2, H-13), 5.07 (1H t, J ) 7 Hz, H-7′′), 3.34 (obscured by solvent, H-7), 3.27 (obscured by solvent, H-1′′), 2.11 (2H t, J ) 7.8 Hz, H-12a), 2.04 (4H t, J ) 7.8 Hz, H-11 and H-6′′a), 1.93 (2H t, J ) 7.2 Hz, H-5′′), 1.75 (3H s, H-4′′), 1.72 (3H s, H-10), 1.64 (3H s, H-16c), 1.62 (3H s, H-10′′c), 1.58 (3H s, H-15 b), 1.56 (3H s, H-9′′ b); 13C NMR (CD3OD, 125 MHz), δ 157.2 (2C s, C-5′ and C-7′), 146.1 (s, C-2), 144.2 (s, C-1), 137.7 (s, C-3′), 136.6 (s, C-9), 134.8 (s, C-3′′), 132.2 (s, C-14), 132.0 (s, C-8′′), 130.3 (s, C-4), 129.6 (s, C-6), 129.0 (d, C-1′), 127.0 (d, C-2′), 125.5 (d, C-7′′), 125.3 (d, C-13), 124.6 (d, C-2′′), 124.1 (d, C-8), 120.6 (d, C-5), 115.8 (s, C-6′), 111.0 (d, C-3), 105.7 (2C d, C-4′ and C-8′), 41.0 (t, C-5′′), 40.9 (t, C-11), 29.1 (t, C-7), 27.8 (t, C-6′′a), 27.7 (t, C-12a), 25.9 (q, C-10′′c), 25.8 (q, C16c), 23.2 (t, C-1′′), 17.8 (q, C-9′′b), 17.7 (q, C-15b), 16.3 (q, C-4′′), 16.2 (q, C-10) (assignment of 1H and 13C signals with the same superscript may be reversed); FABMS Journal of Natural Products, 1998, Vol. 61, No. 12 1511 (noba, positive mode) 516, 460, 393, 307, 289, 165; HRFABMS 516.3242 (calcd for C34H44O4 516.3240). NCI 60-Cell Cancer Assay Data.17 The tumor cell line subpanels are identified as follows: I (leukemia); II (lung, nonsmall-cell); III (colon); IV (CNS); V (melanoma); VI (ovarian); VII (renal); VIII (prostate); IX (breast). The subpanel and individual cell-line identifiers are given, along with the corresponding negative log GI50, TGI, and LC50 values (molar), respectively, for: schweinfurthin A (1) [I] CCRF-CEM (8.00, 5.68, 4.13), HL-60 (7.80, 6.89, 4.41), K-562 (7.19, 4.85, 4.14), MOLT-4 (7.82, 5.89, 4.24), RPMI-8226 (8.00, 7.68, 4.12), SR (7.15, 4.74, 4.13) [II] A549 (6.85,4.85, 4.39), EKVX (6.80, 4.82, 4.36), HOP-62 (6.92, 4.82, 4.32), HOP-92 (5.59, 4.82, 4.33), NCI-H226 (5.35, 4.80, 4.15), NCI-H23 (5.49, 4.74, 4.29), NCI-H322M (5.21, 4.68, 4.32), NCI-H460 (7.89, 4.92, 4.41), NCI-H522 (5.59, 5.00, 4.57) [III] COLO205 (5.96, 5.55, 5.15), HCC-2998 (6.30, 5.01, 4.48), HCT-116 (7.28, 4.85, 4.39), HCT15 (5.74, 5.22, 4.59), HT29 (6.51, 5.62, 5.26), KM12 (5.82, 4.85, 4.52), SW-620 (6.59, 4.74, 4.35) [IV] SF-268 (5.62, 4.68, 4.13), SF-295 (7.96, 7.28, 4.77), SF-539 (8.00, 5.77, 5.09), SNB-19 (6.59, 4.70, 4.31), SNB-75 (7.82, 6.42, 4.30), U251 (7.60, 4.64, 4.31) [V] LOX IMVI (7.42, 4.77, 4.41), MALME-3M (5.37, 4.70, 4.27), M14 (7.80, 6.49, 5.57), SK-MEL-2 (5.77, 4.89, 4.37), SKMEL-28 (5.34, 4.62, 4.22), SK-MEL-5 (7.04, 5.55, 4.92), UACC257 (5.37, 4.74, 4.36), UACC-62 (6.96, 5.74, 5.20) [VI] IGROV1 (5.89, 4.96, 4.46), OVCAR-3 (5.51, 5.10, 4.66), OVCAR-4 (5.37, 4.62, 4.09), OVCAR-5 (5.19, 4.70, 4.34), OVCAR-8 (5.29, 4.70, 4.24), SK-OV-3 (5.57, 4.80, 4.40) [VII] 786-0 (8.00, 5.52, 4.72), A498 (5.38, 4.64, 4.21), ACHN (5.68, 4.80, 4.40), CAKI-1 (6.89, 4.72, 4.25), RXF-393 (8.00, 5.68, 4.26), SN12C (5.16, 4.60, 4.21), TK-10 (5.59, 4.77, 4.38), UO-31 (8.00, 6.68, 5.44) [VIII] PC-3 (6.77, 4.89, 4.44), DU-145 (5.92, 4.82, 4.27) [IX] MCF7 (7.57, 5.09, 4.07), MCF7/ADR-RES (5.42, 4.89, 4.38), MDA-MB-231 (5.38, 4.60, 4.15), HS 578T (8.00, 6.12, 4.06), MDA-MB-435 (5.42, 4.48, 4.13), MDA-N (5.55, 4.59, 4.21), BT-549 (4.89, 4.49, 4.13), T-47D (5.49, 4.66, 4.01). Schweinfurthin B (2) [I] CCRF-CEM (6.64,5.20, 4.00), HL60 (7.43, 5.89, 4.00), K-562 (6.46, 5.21, 4.44), MOLT-4 (7.32, 5.28, 4.96), RPMI-8226 (7.82, 6.96, 4.92), SR (6.59, 4.92, 4.23) [II] A549 (6.47,4.85, 4.41), EKVX (6.03, 4.85, 4.42), HOP-62 (6.07, 4.85, 4.39), HOP-92 (6.03, 4.89, 4.38), NCI-H226 (5.66, 4.85, 4.11), NCI-H23 (5.49, 4.72, 4.29), NCI-H322M (5.47, 4.77, 4.37), NCI-H460 (6.57, 4.89, 4.24), NCI-H522 (5.52, 4.77, 4.40) [III] COLO205 (6.21, 5.62, 5.17), HCC-2998 (5.44, 4.96, 4.46), HCT-116 (6.24, 5.18, 4.64), HCT-15 (5.72, 5.16, 4.47), HT29 (6.43, 5.68, 5.26), KM12 (5.89, 5.03, 4.74), SW620 (6.17, 5.51, 4.77) [IV] SF-268 (5.36, 4.62, 4.12), SF-295 (7.62, 6.54, 5.41), SF-539 (6.82, 5.70, 4.85), SNB-19 (6.40, 4.80, 4.39), SNB-75 (7.60, 5.74, 4.22), U251 (6.70, 4.62, 4.31) [V] LOX IMVI (6.42, 4.77, 4.51), MALME-3M (5.06, 4.57, 4.16), M14 (6.85, 5.92, 5.38), SK-MEL-2 (5.74, 4.77, 4.33), SK-MEL-28 (5.96, 4.89, 4.28), SK-MEL-5 (6.68, 5.05, 4.54), UACC-257 (5.24, 4.68, 4.33), UACC-62 (6.48, 5.64, 5.00) [VI] IGROV1 (5.62, 4.74, 4.37), OVCAR-3 (5.41, 4.89, 4.37), OVCAR-4 (4.92, 4.30, 4.11), OVCAR-5 (5.15, 4.72, 4.35), OVCAR-8 (4.96, 4.57, 4.19), SK-OV-3 (5.59, 4.80, 4.39) [VII] 786-0 (7.66, 5.72, 4.85), A498 (5.77, 4.77, 4.35), ACHN (5.37, 4.70, 4.36), CAKI-1 (5.72, 4.54, 4.12), RXF-393 (8.00, 6.57, 5.15), SN12C (4.92, 4.54, 4.17), TK-10 (5.21, 4.66, 4.28), UO-31 (7.12, 6.04, 5.28) [VIII] PC-3 (6.60, 4.89, 4.37), DU-145 (5.47, 4.72, 4.30) [IX] MCF7 (6.70, 5.22, 4.41), MCF7/ADR-RES (5.16, 4.52, 4.12), MDA-MB-231 (5.19, 4.42, 4.09), HS 578T (7.70, 5.96, 4.00), MDA-MB-435 (5.12, 4.48, 4.14), MDA-N (5.47, 4.82, 4.54), BT-549 (4.96, 4.40, 4.08), T-47D (4.96, 4.16, 4.00). Acknowledgment. We thank Jennifer Michael for technical help, Dominic Scudiero and Anne Monks for 60-cell cancer tests, Tom McCloud for extraction of the plant material, Duncan Thomas and Missouri Botanical Garden under contract to the National Cancer Institute for collection and identification of the plant material, and Lewis Pannell for mass spectra. References and Notes (1) Webster, G. Ann. Missouri Bot. Garden 1994, 81, 33-144. 1512 Journal of Natural Products, 1998, Vol. 61, No. 12 Downloaded by NATL CANCER INST FCRDC on September 8, 2009 | http://pubs.acs.org Publication Date (Web): October 24, 1998 | doi: 10.1021/np980208m (2) Thoison, O.; Hnawia, E.; Guéritte-Voegelein, F.; Sévenet, T. Phytochemistry 1992, 31, 1439-1442. (3) Hnawia, E.; Thoison, O.; Guéritte-Voegelein, F.; Bourret, D.; Sévenet, T. Phytochemistry 1990, 29, 2367-2368. (4) Schütz, B. A.; Wright, A. D.; Rali, T.; Sticher, O. Phytochemistry 1995, 40, 1273-1277. (5) Sultana, S.; Ilyas, M. Phytochemistry 1986, 25, 953-954. (6) Hui, W. H.; Ng, K. K.; Fukamiya, N.; Koreeda, M.; Nakanishi, K. Phytochemistry 1971, 10, 1617-1620. (7) Lin, J.-H.; Nonaka, G.-I.; Nishioka, I. Chem. Pharm. Bull. 1990, 38, 1218. (8) Beutler, J. A.; Alvarado-Lindner, A. B.; McCloud, T. G. Ann. Missouri Bot. Garden 1996, 83, 530-533. (9) Beutler, J. A.; Alvarado, A. B.; McCloud, T. G.; Cragg, G. M. Phytotherapy Res. 1989, 3, 188-192. (10) Boyd, M. R. In Cancer Drug Discovery and Development, Vol. 2, Drug Development: Preclinical Screening, Clinical Trial and Approval; Teicher, B., Ed.; Humana Press: Totowa, NJ, 1997; pp 23-42. (11) Beutler, J. A.; Cardellina, J. H., II.; McMahon, J. B.; Shoemaker, R. H.; Boyd, M. R. In Phytochemistry of Medicinal Plants; Arnason, J. Beutler et al. T., Romeo, J. T., Eds. Plenum: New York, 1995, Chapter 3; pp 4764. (12) Paull, K. D.; Shoemaker, R. H.; Hodes, L.; Monks, A.; Scudiero, D. A.; Rubinstein, L.; Plowman, J.; Boyd, M. R. J. Nat. Cancer Inst. 1989, 81, 1088-1092. (13) Boyd, M. R.; Paull, K. D.; Rubinstein, L. R. In Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development; Valeriote, F. A., Corbett, T., Baker, L., Eds. Kluwer Academic: Amsterdam, 1992; pp 11-34. (14) McCormick, J. L.; McKee, T. C.; Cardellina, J. H., II.; Boyd, M. R. J. Nat. Prod. 1996, 59, 469-471. (15) Pettit, G. R.; Inoue, M.; Kamano, Y.; Herald, D. L.; Arm, C.; Dufresne, C.; Christie, N. D.; Schmidt, J. M.; Doubek, D. L.; Krupa, T. S. J. Am. Chem. Soc. 1988, 110, 2006-2007. (16) Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Boyd, M. R. J. Nat. Cancer Inst. 1991, 83, 757-766. NP980208M